Publication | Closed Access

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Surgical OncologyMalignant Pleural MesotheliomaMedicinePathologyPleural DiseaseSafety Run-inCancer TreatmentFirst-line ChemotherapyOncologyRadiation Oncology